Vical, Inc. (NASDAQ:VICL)
CAPS Rating:
The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.
RSS Headlines
Fool UK
Recs
AS A PHARMACIST I FEEL THE FUTURE IN DRUGS IS IN THE VACINE FIELD, WHICH VICL EXCELS. WITH MONEY FROM MERCK, AND SNY. I FEEL THAT THIS STOCK WILL MOVE UP NEXT YEAR AND FEEL THAT THE SELL OFF THAT IS NOW GOING ON IS A TAX RELIEF SELL OFF.